Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
114.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
197
Open
114.15
Bid (Size)
107.46 (1)
Ask (Size)
118.98 (5)
Prev. Close
114.15
Today's Range
114.15 - 114.15
52wk Range
103.63 - 157.98
Shares Outstanding
100,900,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
September 30, 2024
Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.
Via
The Motley Fool
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
September 30, 2024
In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition.
Via
Chartmill
Performance
YTD
-13.35%
-13.35%
1 Month
-8.75%
-8.75%
3 Month
-16.98%
-16.98%
6 Month
-17.13%
-17.13%
1 Year
+2.11%
+2.11%
More News
Read More
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.
September 26, 2024
Via
Chartmill
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
September 19, 2024
Via
Chartmill
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
September 13, 2024
Via
Benzinga
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
September 09, 2024
Via
Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
September 09, 2024
Via
Chartmill
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
August 19, 2024
Via
Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
September 08, 2024
Via
Benzinga
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
September 05, 2024
Via
Chartmill
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
September 02, 2024
Via
Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
August 19, 2024
Via
Chartmill
Why Neurocrine Biosciences Stock Was Tumbling This Week
August 30, 2024
Via
The Motley Fool
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
August 29, 2024
Via
Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
August 29, 2024
Via
Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
August 28, 2024
Via
Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Via
Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
August 19, 2024
Via
Chartmill
US Stocks Mixed; JM Smucker Slashes Annual Guidance
August 28, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
Via
Investor's Business Daily
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Via
Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
August 22, 2024
Via
Chartmill
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
Via
PressReach
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.